LQDALiquidia Corporation

HealthcareUSD
$71.35

Price

$71.35+271%1Y
1M-20%1Y+271%

Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.

Smart Score

Above average
8/10
Value10
Quality86
Momentum95
Growth97
Strongest Growth, weakest Value · ranked vs Healthcare peers. The five questions below judge the company on its own terms.
What they do

We are a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases such as pulmonary arterial hypertension (“PAH”) and pulmonary hypertension associated with interstitial lung disease (“PH-ILD”). We operate through our wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC, formerly known as RareGen.

In the company’s own words · 10-K filed Mar 5, 2026 · SEC EDGAR

P/E (TTM)51.3
Market Cap$6.32B
1Y Return+271%
5Y Return+2923%

Liquidia Corporation (LQDA) reported revenue of $172M in Q2 2026 (quarter ended June 30, 2026), up 1843% from the same quarter a year earlier. That came with net income of $75M (44% of revenue). For the full year FY2025, revenue was $158M (+1031% year on year) and net income −$69M.

Raw charts

10 series · TTM

As reported to the SEC, without any scoring.

Drug Manufacturers - Specialty & Generic

Ranks #17 of 28 by Smart Score

Compare peers
LNTH+4.0%
Lantheus Holdings, Inc.
HIMS+0.03%
Hims & Hers Health, Inc.
AMRX+0.29%
Amneal Pharmaceuticals, Inc.
ALKS+4.7%
Alkermes plc
INDV-0.43%
Indivior Pharmaceuticals, Inc.
KNSA-3.8%
Kiniksa Pharmaceuticals International, plc